DRREDDY

reported a temporary delay in commercial supplies of its generic semaglutide due to API quality issues. Manufacturing partner OneSource Specialty Pharma Limited said the issue is not expected to have any material financial or operational impact, while the sizeable GLP-1 therapy market continues to offer significant long-term growth opportunities.